Archive

July 2025

Browsing

European stock markets opened broadly higher on Wednesday, with the pan-European Stoxx 600 index jumping as investors cheered the signing of a major trade deal between the United States and Japan.

This development has ignited optimism that a similar agreement could be reached with the European Union, temporarily overshadowing a mixed bag of corporate earnings reports.

About 10 minutes after the opening bell, the pan-European Stoxx 600 was last seen up by a strong 0.9%, with the tariff-sensitive autos sector leading the charge with a remarkable jump of 3.5%.

This follows a positive session in Asia-Pacific markets overnight, which had also reacted favorably to the US-Japan trade deal, where a baseline tariff of 15% was set on Japan’s exports to the United States.

The upbeat mood in Europe was further fueled by reports of comments made by US President Donald Trump at a dinner in Washington on Tuesday. He reportedly told guests that EU delegates were “coming in tomorrow, the next day,” suggesting that high-level negotiations are imminent and potentially productive.

This has provided a much-needed dose of optimism for markets that had declined again on Tuesday, as investors digested a slew of earnings and weighed the prospect of steep US trade tariffs kicking in on August 1 if a deal isn’t reached.

Futures data from IG had already signaled a positive open for European indexes, with London’s FTSE 100 seen opening 0.6% higher, France’s CAC 40 up 1.2%, Germany’s DAX up 1%, and Italy’s FTSE MIB also 1.2% higher.

A mixed bag of earnings: Thales up, Nokia down

Wednesday is a busy day for corporate financial updates, with several major companies reporting their latest results, presenting a mixed picture for investors.

  • Iberdrola: The Spanish electricity utilities giant posted a 14% year-on-year decline in its first-half net profit, which came in at 3.6 billion euros ($4.2 billion).

    The company also announced a 5-billion-euro increase in its share capital, stating that the move would cover its upcoming investment plan.

  • Equinor: The Norwegian energy group saw its adjusted earnings fall by 13% in the second quarter, a result that was in line with expectations. The decline was primarily attributed to lower oil prices.

    The company also booked a significant $955 million impairment on a key offshore wind project in the US, citing regulatory changes and the impact of tariffs.

  • Thales: French defense contractor Thales delivered a positive surprise, raising its full-year sales guidance after reporting stronger-than-expected profit.

    The company’s adjusted operating profit for the first half of the year came in at 1.25 billion euros ($1.47 billion), a 13% jump from the first six months of 2024 and ahead of the 1.23 billion euros anticipated by analysts, according to LSEG data.

    First-half sales grew 8.1% year-on-year to 10.3 billion euros, which Thales attributed largely to “a solid performance” in its aerospace and defense divisions.

    However, even in its upbeat report, Thales acknowledged the lingering trade risks, stating that it was still anticipating “a contained direct impact of tariffs” that could be imposed on EU goods by the Trump administration.

    The company’s guidance, it clarified, was based on the assumption of 10% reciprocal tariffs and excluded any potential retaliatory measures from European leaders.

  • Nokia: In a starkly negative development, shares of Finnish telecoms giant Nokia were down 7% in early trade on Wednesday after the company issued a profit warning.

    Nokia lowered its comparable operating profit guidance range to 1.6 billion euros to 2.1 billion euros ($1.9 billion to $2.5 billion), down from its previous expectation of a range between 1.9 billion euros and 2.4 billion euros.

The post Europe markets open: stocks rise; autos jump 3.5% on trade optimism; Nokia down appeared first on Invezz

The cannabis market has faced unexpected challenges in 2025, despite initial optimism for rescheduling in the US. 

While US federal regulatory uncertainty and banking remain persistent, companies are shifting focus to match changes in consumer behavior. The growing popularity of edibles and rising interest in cannabis-infused beverages reflect evolving demand in a persevering industry.

Cannabis companies in the sector continue to move forward and develop their offerings, and with potential catalysts ahead, some investors are interested in getting involved. Looking at the key players is often a good place to get started, so this list of US and Canadian cannabis stocks covers the companies with the largest presence in two major cannabis ETFs.

This list of the biggest publicly traded cannabis companies was put together based on the top-weighted cannabis stocks included in the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS) and the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) as of July 16, 2025. Share price information for the companies was accurate as of that time.

US cannabis market

Cannabis is federally illegal in the US, but state market openings have allowed some operators to thrive. Typically these firms set up vertically integrated businesses with a focus on branded products, retail networks and licenses.

While these companies have adapted to regulatory challenges, they have much to gain from country-level reform in the US, and are eager to see more welcoming federal laws that will allow their businesses to develop further.

Top cannabis stocks in the AdvisorShares Pure US Cannabis ETF

The AdvisorShares Pure US Cannabis ETF provides exposure to public companies exclusively operating within the US cannabis industry. By investing in companies that are working in states with clear guidelines, MSOS gives investors a way to be more selective about the types of cannabis companies they’re investing in.

1. Green Thumb Industries (CSE:GTII,OTCQX:GTBIF)

ETF weight: 32.06 percent
Market cap: US$1.36 billion
Share price: US$5.72

Green Thumb Industries is a multi-state operator (MSO) with headquarters in Chicago, Illinois.

The company is involved in the entire process of the industry, from cultivating and producing cannabis products to selling them in its own retail stores, of which there are many across the United States. Green Thumb Industries owns a portfolio of well-known cannabis brands like Rythm, Beboe, Dogwalkers, Incredibles and Doctor Solomon’s.

2. Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF)

ETF weight: 22.59 percent
Market cap: US$781.51 million
Share price: US$4.09

Trulieve is another major player in the cannabis industry, with a strong focus on medical cannabis. The company offers a diverse selection of cannabis products, including flower, pre-rolls, concentrates, edibles, topicals and more.

Vertically integrated, Trulieve Cannabis has a dominant market share in its home state of Florida, as well as in Arizona and Pennsylvania. In June 2024, the company opened its 200th dispensary in the United States.

3. Curaleaf Holdings (TSX:CURA,OTCQX:CURLF)

ETF weight: 15.37 percent
Market cap: US$764.16 million
Share price: US$1.00

Curaleaf Holdings has a significant presence in the US cannabis market, with around 150 dispensaries and several cultivation centers across 17 states. The company is also continuing its expansion into the European cannabis sector, where it already has a strong presence. Curaleaf has a wide range of brands covering a variety of cannabis product types, including flower, vapes, edibles and hemp-derived THC beverages.

4. Glass House Brands (CBOE:GLAS.A.U,OTC Pink:GHBWF)

ETF weight: 7.32 percent
Market cap: US$269.57 million
Share price: US$5.40

Glass House Brands is a vertically integrated cannabis company with a focus on the California market. The company is has placed an emphasis on sustainable practices at its large-scale cultivation facility in Camarillo, California. Glass House Brands is also a major producer and wholesaler of cannabis biomass and cannabis oil to other manufacturers and extractors in the industry.

Glass House offers a diverse range of cannabis products through its various brands and retail operations, including edibles and wellness products under its Mama Sue Wellness brand.

5. Cresco Labs (CSE:CL,OTCQX:CRLBF)

ETF weight: 5.53 percent
Market cap: US$235.9 million
Share price: US$0.53

Cresco Labs is a vertically integrated multi-state cannabis operator in the United States. A leading US cannabis company, it is known for its strong brands like Cresco, High Supply and Good News.

Cresco Labs controls its supply chain from cultivation to retail, offering a wide range of products. While it has its own stores, it focuses heavily on wholesale, getting its products into dispensaries across the country.

Canadian cannabis market

In 2018, Canada became the first G7 nation to legalize adult-use cannabis and create its own streamlined program regulated by both federal and provincial powers. Since then, companies working in the country have faced ups and downs in dealing with tight marketing rules, high tax rates and ongoing competition with the unregulated market.

Top cannabis stocks in the Global X Marijuana Life Sciences Index ETF

The Global X Marijuana Life Sciences Index ETF was the first cannabis ETF available in Canada, and it holds a variety of publicly traded companies involved in cannabis, along with several non-flower companies.

While HMMJ does not invest in US-based multi-state operators, it does have exposure to the US market through Canadian companies that have interests in the US cannabis industry. Overall, HMMJ is designed to give investors broad exposure to the cannabis industry, with a particular focus on North American companies.

1. Jazz Pharmaceuticals (NASDAQ:JAZZ)

ETF weight: 16.47 percent
Market cap: US$7.02 billion
Share price: US$116.08

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing medicines for people with serious diseases, often with limited or no other options. They have a diverse portfolio of products in areas like sleep disorders, cancer and epilepsy.

Jazz Pharmaceuticals’ cannabis business stems from their 2021 acquisition of GW Pharmaceuticals and its epilepsy medicine Epidiolex for a whopping US$7.2 billion. This made big waves as it was one of the largest moves by a traditional pharmaceutical company into the cannabis space.

2. Cronos Group (NASDAQ:CRON,TSX:CRON)

ETF weight: 13.14 percent
Market cap: US$774.69 million
Share price: US$2.01

Cronos Group is the Canada-based company behind the Spinach, Peace Naturals and Lord Jones cannabis brands. In Canada, Cronos’ Spinach brand is in the top three for retail sales in the flower and edible categories.

The company also has a presence in Israel and Germany with its brand Peace Naturals. In late 2023, the company re-entered the German medical cannabis market through its partnership with a German medical cannabis company called Cansativa Group. Cronos serves the Israeli market through its subsidiary Cronos Israel.

3. Innovative Industrial Properties (NYSE:IIPR)

ETF weight: 11.28 percent
Market cap: US$1.51 billion
Share price: US$53.99

Innovative Industrial Properties is a real estate investment trust that provides specialized real estate opportunities for cannabis companies in 19 states. Its properties mostly consist of processing plants, greenhouses and warehouses, with retail spaces making up a small percentage of its portfolio.

The firm has provided long-term absolute net lease agreements to some of the cannabis industry’s biggest names, including Green Thumb, TILT Holdings (NEO:TILT,OTCQB:TLLTF), Ascend Wellness (CSE:AAWH.U,OTCQX:AAWH) and Curaleaf. The company’s sale-leaseback program has helped cannabis companies access a source of capital, a much-needed workaround in the US where there are fewer traditional financing options.

4. Scotts Miracle-Gro Co (NYSE:SMG)

ETF weight: 10.74 percent
Market cap: US$3.92 billion
Share price: US$67.92

Scotts Miracle-Gro is a leader in lawn and garden products, but its involvement in the cannabis industry comes through its Hawthorne Gardening Company subsidiary. Hawthorne is an ancillary provider, supplying essential hydroponic and indoor growing equipment, nutrients, lighting and environmental control systems for large-scale cannabis production.

5. SNDL (NASDAQ:SNDL)

ETF weight: 7.8 percent
Market cap: US$383.4 million
Share price: US$1.49

SNDL, formerly known as Sundial Growers, is the largest private-sector liquor and cannabis retailer on the Canadian market. They cultivate and sell cannabis products under various brands, including Top Leaf, Sundial Cannabis, Palmetto and more. They focus on premium indoor cultivation and have a strong presence in the Canadian market.

SNDL has faced financial challenges in the past, but in Q1 2025 the company’s cannabis business revenue grew year-over-year for the 13th consecutive quarter. The company has continued to make strategic investments in 2025.

FAQs for investing in cannabis

Are cannabis stocks worth investing in?

Each investor will have to think and act for themselves to manage their own risk exposure, but it’s no secret that cannabis stocks have taken a beating for some time now. While financial experts point to the long-term upside of US operators as more state markets expand, the stock market has not been kind to these names lately.

Are cannabis stocks considered a high- or low-risk investment?

Cannabis investments are extremely young in the grand scheme of the investment universe. There is an exciting and refreshing element to these stocks, but the market has always been characterized by volatility and unpredictability.

While wild, spontaneous swings in the open market have become less common, cannabis stocks are often moved — both positively and negatively — by big pieces of market news or legalization updates.

Why do people buy cannabis stocks?

Investors may choose to get exposure to the cannabis market as a way to participate in the development of a new drug market with consumer packaged goods capabilities. Some participants are bullish on the industry’s long-term outlook and expect more welcoming laws in the US and across the world to provide upward momentum.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Elon Musk’s health tech company Neuralink labeled itself a “small disadvantaged business” in a federal filing with the U.S. Small Business Administration, shortly before a financing round valued the company at $9 billion.

Neuralink is developing a brain-computer interface (BCI) system, with an initial aim to help people with severe paralysis regain some independence. BCI technology broadly can translate a person’s brain signals into commands that allow them to manipulate external technologies just by thinking.

Neuralink’s filing, dated April 24, would have reached the SBA at a time when Musk was leading the Trump administration’s Department of Government Efficiency. At DOGE, Musk worked to slash the size of federal agencies.

MuskWatch first reported on the details of Neuralink’s April filing.

According to the SBA’s website, a designation of SDB means a company is at least 51% owned and controlled by one or more “disadvantaged” persons who must be “socially disadvantaged and economically disadvantaged.” An SDB designation can also help a business “gain preferential access to federal procurement opportunities,” the SBA website says.

The Department of Justice has previously fined companies for making false claims about their SDB status.

Musk, the world’s wealthiest person, is CEO of Tesla and SpaceX, in addition to his other businesses like artificial intelligence startup xAI and tunneling venture The Boring Company. In 2022, Musk led the $44 billion purchase of Twitter, which he later named X before merging it with xAI.

Jared Birchall, a Neuralink executive, was listed as the contact person on the filing from April. Birchall, who also manages Musk’s money as head of his family office, didn’t immediately respond to a request for comment.

Neuralink, which incorporated in Nevada, closed a $650 million funding round in early June at a $9 billion valuation. ARK Invest, Peter Thiel’s Founders Fund, Sequoia Capital and Thrive Capital were among the investors. Neuralink said the fresh capital would help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Under Musk’s leadership at DOGE, the initiative took aim at government agencies that emphasized diversity, equity and inclusion (DEI). In February, for example, DOGE and Musk boasted of nixing hundreds of millions of dollars worth of funding for the Department of Education that would have gone towards DEI-related training grants.

This post appeared first on NBC NEWS

U.S. Ambassador to Israel Mike Huckabee lashed out at almost 30 Western countries who on Monday called for Israel to end the war in Gaza, saying in a post on X that ‘when Hamas thinks you do good work, you are doing evil.’

‘How embarrassing for a nation to side w/ a terror group like Hamas & blame a nation whose civilians were massacred for fighting to get hostages released,’ wrote Huckabee after Hamas – whose Oct. 7, 2023, mass terror attack on Israel sparked the ongoing war in Gaza – said it welcomed ‘the contents of the joint statement issued by the United Kingdom Government along with 25 other countries, calling for an immediate end to the war on the Gaza Strip.’

The U.S. and EU-designated terror group also reiterated its claims that Israel was carrying out a ‘policy of starvation’ on the coastal enclave amid unverified reports that people have died due to hunger-related reasons. Fox News Digital has not been able to independently verify such reports.

‘The statement’s condemnation of the killing of over 800 Palestinian civilians at the gates of U.S.-Israeli-controlled aid checkpoints underscores the brutality of this mechanism,’ Hamas wrote following a statement issued by the U.K. Foreign Office and U.K. Foreign Secretary David Lammy.

‘The suffering of civilians in Gaza has reached new depths,’ read Lammy’s statement, which was also signed by the foreign ministers of 28 countries.

‘If Hamas embraces you – you are in the wrong place,’ Israel’s Foreign Minister Gidon Saar responded on X. ‘Hamas’s praise for the statement by the group of countries is the best proof of the mistake they made – part of them out of good intentions and part of them out of an obsession against Israel.’ 

Since launching a new model for food aid distribution in the war-torn strip in early May, Israel and the U.S. have come under fire from the international community over near-daily reports of people dying while attempting to receive aid or not receiving any aid at all.

Israel has refuted claims that there is hunger in Gaza or that it is using starvation as a tactic of the now 22-month-old war. Rather, officials have said they are working to prevent Hamas from stealing aid being distributed by veteran, mostly U.N.-run, humanitarian agencies and sold for exorbitant prices in a bid to continue funding terror operations. 

Israel, which is tasked with securing routes to four aid centers run by the U.S.-backed Gaza Humanitarian Fund, has also denied that its soldiers intentionally kill Palestinian civilians but is rather issuing warning shots as a measure of crowd control. The GHF has so far delivered some 85 million meals since it started its aid operation in May.

U.N. spokesman Stéphane Dujarric said on Monday that Secretary-General Antonio Guterres ‘deplored the growing reports of both children and adults suffering from malnutrition and strongly condemned the ongoing violence, including the shooting, killing and injuring of people attempting to get food.’

‘As someone who has spent over 40 years in Israel’s Security Establishment – both as IDF Chief of Staff & Minister of Defense, I can say this unequivocally: Not only has Israel never starved or targeted civilians, but it goes above and beyond to protect civilians in the most complex of war zones like Gaza,’ Israeli opposition leader Benny Gantz wrote on X.

‘We must be clear – culpability for harm inflicted to civilians rests on terrorist Hamas and Hamas only,’ he added. 

On Tuesday, Dr. Mohammed Abu Salmiya, director of Al-Shifa Medical Complex in Gaza, said in a statement that ‘twenty-one children have died due to malnutrition and starvation in various areas across the Gaza Strip.’ 

‘Every moment, new cases of malnutrition and starvation are arriving at Gaza’s hospitals,’ he said.  

Kobi Michael, a senior researcher at the Institute for National Security Studies in Tel Aviv who has been monitoring the situation in Gaza closely, told Fox News Digital that he was ‘not aware of a single official report that people died because of starvation or hunger.’ 

‘I’m not familiar with any such report, but I am familiar with many warnings that were published by international organizations about the catastrophe that exists in Gaza and how in two months or so, 40 or 50,000 people will die because of hunger, but nobody has died because of hunger, because there is no hunger,’ he said, adding, ‘if there are some local problems of supply, it is because of Hamas – not because of the IDF.’

Michael, who is also a fellow at the Misgav Institute in Jerusalem, pointed out that Hamas ‘loots, robs and steals the humanitarian aid, partially for themselves, to feed themselves and the rest is sold in very high prices to the local population in order to make money.’

Israel’s goal of weakening Hamas’s grip on the Strip – and on aid agencies – appeared to be working on Monday, with The Washington Post reporting that the terror group ‘is facing its worst financial and administrative crisis in its four-decade history’ and is struggling to find the resource it needs to continue fighting Israel or rule Gaza. 

Quoting a former high-level Israeli intelligence officer, and current Israel Defense Forces officers, the report said that Hamas could no longer pay its fighters or rebuild its underground terror tunnels, where it is believed to be holding some 50 hostages, both alive and dead, who kidnapped during its Oct. 7 attack. 

This post appeared first on FOX NEWS

AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes building its largest-ever manufacturing facility in Virginia and expanding research and development across several states.

The move comes as global pharmaceutical firms face mounting pressure to relocate production to the United States amid the prospect of steep trade tariffs under the Trump administration.

The Anglo-Swedish biopharmaceutical company said the investment will bolster US manufacturing and research capabilities, with a particular focus on its weight management and metabolic disease portfolio.

A new multi-billion-dollar facility in Virginia will serve as the cornerstone of the initiative and is set to produce, among other products, its oral GLP-1 obesity drug.

“This will be our largest single manufacturing investment globally,” the company said in a statement, noting that the plant will incorporate artificial intelligence, automation and data analytics to improve efficiency.

AstraZeneca’s US expansion

Beyond the Virginia facility, AstraZeneca’s investment will expand cell therapy manufacturing and R&D operations in Maryland, Massachusetts, California, Indiana and Texas.

The company said the initiative would create “tens of thousands of jobs” as it deepens its presence in the world’s largest pharmaceutical market.

CEO Pascal Soriot said the move reflects the company’s confidence in the US as a global leader in life sciences.

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,” Soriot said.

AstraZeneca expects half of that projected revenue to come from the US market.

AstraZeneca, which played a major role in the global rollout of COVID-19 vaccines, has steadily increased its US footprint in recent years.

The company reported that the United States accounted for over 40% of its annual revenue in 2024.

In November, it announced a $3.5 billion US investment shortly after the US presidential election.

Earlier this month, The Times reported that AstraZeneca was considering a potential move of its primary listing from London to a US exchange, a shift that analysts described as a blow to the United Kingdom’s public markets.

The company is the most valuable constituent of the FTSE 100 index.

Industry-wide repositioning in response to Trump tariffs

The announcement places AstraZeneca among a growing list of global pharmaceutical companies—including Novartis, Sanofi, Roche, Eli Lilly and Johnson & Johnson—that have pledged to ramp up US investment in recent months.

The moves follow policy signals from US President Donald Trump, who has advocated for reshoring domestic manufacturing and warned the pharmaceutical industry to prepare for aggressive trade measures.

A pending Section 232 investigation into the pharmaceutical sector is expected to conclude by the end of July, with the administration weighing tariffs that could reach as high as 200%.

Trump has proposed a 12- to 18-month grace period to allow pharmaceutical firms to realign their supply chains, though industry leaders have pushed back, citing logistical constraints.

“Typically for most medicines it’s a three to four year horizon,” Novartis CEO Vas Narasimhan said on an earnings call last week.

“We’re working very hard to accelerate that as fast as we can and demonstrate we’re making the investments we have planned,” he added.

As the tariff landscape evolves, AstraZeneca’s announcement signals a broader industry shift to mitigate regulatory risk and secure access to the US market, which remains a key growth driver for the sector.

The post AstraZeneca commits $50B to US expansion amid Trump tariff pressure appeared first on Invezz

The second quarter of 2025 brought more downward pressure for lithium prices, as values for lithium carbonate continued to contract, slipping to their lowest level since January 2021.

After starting the year at US$10,484.37 per metric ton, battery-grade lithium carbonate rose to a year-to-date high of US$10,853.85 on January 27. Prices sank through Q1 and most of Q2, bottoming at US$8,329.08 on June 24.

Lithium hydroxide followed a similar trajectory, with Fastmarkets analysts noting an 89 percent drop in prices for battery-grade lithium hydroxide monohydrate between 2022 and 2025.

“The lithium industry is definitely navigating a period of complexity,” said Paul Lusty, head of battery raw materials at Fastmarkets, at Fastmarkets’ Lithium Supply & Battery Raw Materials conference in June.

“We’re facing headwinds, no doubt, and we’re also seeing quite a lot of negative or bearish sentiment widespread in the market, and I think at times, it’s amplified by voices that really overlooked the phenomenal levels of demand that we’re seeing in many aspects of the market.”

However, Lusty explained that despite facing a multi-quarter price slump, lithium’s long-term drivers remain robust, and are primarily driven by what he described as “mega trends.”

“The fundamentals are really still very strong, and these are anchored in some very powerful, mega trends that we see developing within the global economy; the urgent drive for climate change mitigation, the once in a generational shift in the global energy system, and also the rise of energy intensive technologies such as artificial intelligence,” he said.

Chinese expansions behind lithium oversupply

Although the long-term outlook for lithium remains positive, oversupply and market saturation have added headwinds during the first half of 2025. Demand, particularly from the electric vehicle (EV) sector, remains strong, but global lithium mine supply has outpaced it, rising by an estimated 22 percent in 2024 alone.

“We’re forecasting similar year on year increases for both 2025 and 2026 equivalent to around 260,000 tons of additional (lithium carbonate) alone just this year,” explained Fastmarkets’ Lusty.

“Chinese producers have been particularly aggressive in terms of expanding capacity.” Australia, Argentina and Chile are also driving growth alongside emerging producers like Brazil, and several African nations.

According to data from the US Geological Survey, mined supply from China increased 14.85 percent from 35,700 metric tons in 2023 to 41,000 in 2024, however an asterisk notes that the tallies are estimates, and exact numbers may be “withheld to avoid disclosing company proprietary data.”

For Fastmarkets, the total is likely higher.

“China has rapidly expanded its mining footprint, boosting domestic lithium output by 55 percent since 2023 and is on track to surpass Australia as the world’s top producer by 2026,’ said Lusty. “One of the most notable developments has been the rise of African supply that we started to see over the last two years,” said Lusty.

Africa’s emerging role in the lithium sector

The importance of African supply to the future lithium market was also the topic at Claudia Cook’s presentation, ‘The Lithium Market Shift: China’s and Africa’s Role in Redefining Supply.’

During the 20 minute overview Cook explained that China is increasingly looking to African hard-rock lithium supply to provide feedstock for the country’s growing chemical segment.

So much so that by 2030 18 percent of global hard-rock lithium supply will originate from the continent.

Additionally, the continent will see a 170 percent uptick in hard-rock lithium supply output between 2025 and 2035, according to Cook, who attributes the massive expansion to China’s need to diversify its lithium sources due to domestic supply constraints. To facilitate this demand, China has invested heavily in African production.

“In 2025, 79 percent of African output will be China owned,” she said. “That percentage reduces down to 65 percent in 2035 however, with the increase in tonnage, even though there’s a reduction in percentage, there’ll be an almost doubling in terms of how much that’s actually being put out.”

Regionally, Cook pointed to Zimbabwe and Mali as the country’s poised to see the most growth.

In 2025, Zimbabwe alone is expected to account for 70 percent of African lithium supply, though its share is projected to fall to 43 percent by 2035 as new countries come online.

Despite that shift, African output overall is set to rise significantly, with nations like the DRC, Ethiopia, and Namibia expected to begin production by 2035, said Cook.

Lithium demand surges, but prices lag

The rapid increase in supply has pushed prices to multi year lows, levels that are unsustainable and fail to incentivize new production. Despite this demand remains strong and is expected to grow.

According to the US Geological Survey, global consumption of lithium in 2024 was estimated to be 220,000 tons, a 29 percent increase from revised consumption of 170,000 tons in 2023.

Much of the demand story is attributed to soaring global EV sales, which were up 35 percent in Q1. Lithium consumption in this segment is projected to grow 12 percent annually through 2030.

“Globally, electric car sales this year are forecast to surpass about 20 million units in 2025 representing more than a quarter of all cars sold,” said Lusty.

Future lithium demand remains underpinned by deep structural shifts in global energy consumption.

“We’re witnessing extraordinary battery demand tied to the electrification of the global economy and the rise of renewable energy,” said Lustyt, pointing to surging electricity needs and the increasing role of storage solutions.

In 2024, global electricity demand rose by over 4 percent, adding 1,100 terawatt-hours to the grid, more than Japan’s total annual consumption. This marks the largest year-on-year increase outside post-recession rebounds and reflects broad trends such as greater electricity access, the proliferation of energy-intensive appliances, the expansion of artificial intelligence and data centers, and the shift to electric-powered heavy manufacturing.

Notably, 95 percent of future demand growth is expected to be met by renewables like solar and wind, further boosting the need for battery energy storage systems (BESS) to manage intermittency and stabilize grids.

“Batteries are now essential — not just for EVs, but to balance power systems across sectors,” Lusty added.

Data centers, in particular, are becoming a key growth driver. Since 2017, their electricity use has grown 12 percent annually, according to Fastmarkets, with the US seeing half its centers concentrated in five regional hubs.

By 2030, BESS demand from data centers alone could represent a third of the market, with a projected compound annual growth rate of 35 percent over the next five years.

Overall, lithium demand is forecast to grow 12 percent annually through 2030, underpinned by EV adoption, renewable integration, and digitalization. While China currently accounts for 60 percent of global demand, that dominance is expected to wane as other regions scale up.

“The long-term fundamentals remain intact,” he said, “and it’s hard to envision a future where lithium isn’t central to the global economy.”

What’s next for lithium in 2025?

After June saw prices slip to year-to-date lows, lithium saw a brief uptick in early July amid speculation about supply cuts from Australian miners Mineral Resources (ASX:MN,OTC Pink:MALRF) and Liontown Resources (ASX:LTR,OTC Pink:LINRF). However, gains were reversed after the rumors were denied.

In the US, policy uncertainty continues to weigh on sentiment. A rollback of EV tax credits under the Trump administration could spark a short-term sales bump, but longer-term support appears fragile.

New fair competition rules in China, aimed at curbing downstream dumping, have fueled speculation about broader impacts. While upstream effects are unclear, the policy contributed to July’s brief price rise.

“The nascency of the lithium market means that it is prone to be led by sentiment,” wrote Cook in a monthly update.

‘We have especially seen this at play this month as prices ticked up momentarily mainly from rumors of supply cuts, highlighting how twitchy and reactive the market currently is,’ she continued.

‘These rumors have since been denied … However, with healthy inventory levels and continued ramp-up of production, the reported supply cuts, even if they proved true, may not be enough to dip the market into a deficit.”

Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Senate Republican leadership is weighing whether to cancel, or shorten, their upcoming August break following President Donald Trump’s request to stay in town and finish confirming his outstanding nominees. 

Over the last six months, the Senate has moved at a breakneck pace to confirm the president’s nominees all while facing resistance from Senate Democrats. So far, 96 of Trump’s nominees have been confirmed. Still, there are 136 outstanding nominations on the upper chamber’s calendar that haven’t made it over the finish line.

Year in and year out, lawmakers typically escape from the Hill for the entire month of August, either recuperating from months in Washington, D.C., or selling their legislative accomplishments to people back home.

But Trump on Sunday called on Senate Majority Leader John Thune, R-S.D., to keep lawmakers in town to finish their work on confirming his slew of outstanding nominees.

‘Hopefully the very talented John Thune, fresh off our many victories over the past two weeks and, indeed, 6 months, will cancel August recess (and long weekends!), in order to get my incredible nominees confirmed,’ Trump said on his social media platform Truth Social. ‘We need them badly!!! DJT’

Thune said he had spoken with the president about the August recess issue, but did not say whether the entire break would be canceled. A senior GOP aide told Fox News Digital that discussions over shortening the August recess were already happening before Trump’s request.

‘We’re thinking about it,’ Thune said. ‘We want to get as many noms through the pipeline as we can. And honestly, it’d be nice to have Democrats who actually would kind of act more according to historical precedents when it comes to this.’

The remaining spots that need to be filled run across nearly every facet of the federal government, including positions in the Defense Department, Environmental Protection Agency, Commerce Department and a slew of ambassadors, among others.

Among the remaining nominees are some familiar faces from the 2024 election and beyond, including Hung Cao, who ran against Sen. Tim Kaine, D-Va., and was nominated as Navy undersecretary; Donald Trump Jr.’s ex-fiancee Kimberly Guilfoyle, who was tapped to be the U.S. ambassador to Greece, and former Rep. Marc Molinaro, R-N.Y., who was nominated to be Federal Transit administrator.

Thune accused Senate Democrats of being obstructionist and noted that so far, not a single nominee has been approved through the fast-track voice vote or unanimous consent processes. Indeed, every nominee has been put to a floor vote. Only Secretary of State Marco Rubio received a near unanimous, 99 to 0, vote.

Earlier this year, Senate Minority Leader Chuck Schumer, D-N.Y., supported delaying all the president’s nominees who lack unanimous support in the upper chamber, effectively triggering floor votes for each. He also used an arcane Senate procedural move to stall federal prosecutors in committee.

‘This is something that we’re very committed to, and we’re going to be looking at all the options in the next few weeks to try and get as many of those across the finish line as we can,’ Thune said. 

This post appeared first on FOX NEWS

Shares of Reliance Industries Ltd (RIL) dropped over 2.5% in Monday’s trading session, as investors appeared unimpressed by the conglomerate’s highest-ever quarterly profit and EBITDA performance, amid underwhelming results in its key retail and oil-to-chemicals (O2C) segments.

The stock opened at ₹1,465 per share, below the previous close of ₹1,476, and declined further to ₹1,439 by noon, down 2.5%.

This came despite the Mukesh Ambani-led firm posting a 76% year-on-year jump in consolidated net profit for the April-June quarter of FY26.

Strong top-line and profitability gains in Q1

Reliance reported consolidated profit after tax (PAT) of ₹30,681 crore for the first quarter of FY26, significantly ahead of analysts’ estimates and up from ₹17,448 crore in the same quarter a year ago.

Consolidated EBITDA rose 35.7% to ₹58,024 crore, marking the group’s best quarterly performance to date.

Revenue grew 6% year-on-year to ₹2,73,252 crore.

Chairman Mukesh Ambani said, “Reliance has begun FY26 with a robust, all-round operational and financial performance. Consolidated EBITDA improved strongly from the year-ago period, despite significant volatility in global macros.”

The EBITDA margin improved by 460 basis points to 21.2% from 16.6% last year, reflecting improved cost efficiencies and growth in high-margin segments.

Retail and oil-to-chemicals fail to meet analyst expectations

Despite the strong headline numbers, earnings in the O2C and retail segments came in lower than expected, tempering the market’s response.

The company cited planned maintenance shutdowns at its Jamnagar refinery and seasonal weakness in consumer electronics as key factors affecting performance.

Nomura flagged a weaker-than-anticipated show in retail and O2C, attributing it to maintenance activities and elevated feedstock and freight costs.

CLSA noted that a 3% miss in O2C EBITDA and a 5% miss in retail EBITDA overshadowed strong showings from the upstream and telecom unit Jio.

Brokerages raise price targets despite market reaction

While the market reacted negatively in the short term, the results prompted at least 10 analysts to raise their target prices on the stock.

Analysts believe the moderation in stock prices may be short-lived.

A rebound in gross refining margins, coupled with Jio’s expansion and recovery in discretionary retail, could drive stronger performance in upcoming quarters.

The median target price has climbed to ₹1,640 from ₹1,565 a month ago.

“Retail and Jio are likely to accelerate, and the new energy ecosystem is expected to fully operationalise in four to six quarters, with partnerships and a self-funded model in a few years,” Emkay analysts said in a note.

Domestic brokerage Motilal Oswal Financial Services cut FY26–27 earnings estimates by 1–4%, but raised its price target slightly to ₹1,700 per share.

“While 1Q was soft, we remain sanguine on RIL’s growth prospects across segments and build in a CAGR of ~11% in EBITDA/PAT over FY25-28E,” the brokerage said.

Jefferies maintained a “buy” rating with a revised target of ₹1,726, acknowledging short-term weakness but expressing optimism about the O2C outlook.

Reliance shares are still up about 19% year-to-date, outperforming the broader Nifty 50 index, which has gained 5.9% in the same period.

As the company navigates operational hurdles and global headwinds, the street appears to be betting on a longer-term story built around telecom, retail expansion, and clean energy transformation.

The post Reliance shares fall despite record profit jump: should you buy? appeared first on Invezz

President Donald Trump celebrated six months since he was sworn into his second term on Sunday, saying that the United States has been ‘totally revived’ after being ‘DEAD’ under former President Joe Biden. 

‘Wow, time flies! Today is that Sixth Month Anniversary of my Second Term. Importantly, it’s being hailed as one of the most consequential periods of any President,’ Trump wrote on social media. 

‘In other words, we got a lot of good and great things done, including ending numerous wars of Countries not related to us other than through Trade and/or, in certain cases, friendship,’ he added on TRUTH Social. ‘Six months is not a long time to have totally revived a major Country.’ 

Trump continued: ‘One year ago our Country was DEAD, with almost no hope of revival. Today the USA is the ‘hottest’ and most respected Country anywhere in the World. Happy Anniversary!!!’ 

Trump’s first six months have been marked by a number of significant moments, particularly on the international stage.

After Iran-backed Houthis in Yemen ramped up attacks on shipping vessels in the Red Sea in late 2024, the Trump administration designated the group a foreign terrorist organization, reinstating a move that had been reversed under Biden.

U.S. and U.K. forces earlier this year pounded Houthi missile and radar sites as part of an operation to ensure freedom of navigation, and the Trump administration secured a ceasefire deal with the terror group in May.  

Trump intervened in the Israel-Iran war in June, ordering U.S. military strikes against Iranian nuclear facilities and infrastructure that pummeled Tehran’s capabilities and forced the regime into quick submission. 

Though Trump had promised on the campaign trail to end the Ukraine-Russia war within 24 hours, a peace agreement between the two sides has so far failed to materialize. 

Earlier in his second term, Trump had slammed Ukrainian President Volodymyr Zelenskyy for a perceived lack of gratitude for billions of dollars in U.S. support to his war effort under Biden’s presidency. Trump more recently has sharpened his criticism of Russian leader Vladimir Putin, slamming Moscow for the massive loss of life on both sides during the more than three-year-long conflict. 

Trump issued a new deadline in mid-July that Russia had 50 days to agree to a ceasefire or face ‘maximum tariffs.’ He also recently approved the sale of additional U.S. Patriot missiles to Ukraine. 

In its first six months, the Trump administration had also brokered a ceasefire between the Democratic Republic of Congo and Rwanda in late June. 

Beyond ‘ending numerous wars,’ Trump has celebrated other accomplishments during his first six months back in office, including securing the passage of his ‘big, beautiful bill,’ which made the 2017 Trump tax cuts permanent. The legislative package also earmarked funding for the president’s other initiatives, including for his mass deportation campaign and border security. 

On overseas trips and at home, Trump has repeatedly said the U.S. is the ‘hottest’ country, claiming to have restored America’s reputation both domestically and on the world stage with his ‘America First’ foreign policy. 

Delivering on his 2024 pledge to make the U.S. the ‘crypto capital of the planet,’ Trump on Friday signed landmark legislation that creates a regulatory regime for dollar-pegged cryptocurrencies known as stablecoins. 

Trump on Sunday also appeared to dismiss concerns that his administration’s handling of the Jeffrey Epstein files could cost Republicans control of Congress in the 2026 midterm elections and beyond. 

‘My Poll Numbers within the Republican Party, and MAGA, have gone up, significantly, since the Jeffrey Epstein Hoax was exposed by the Radical Left Democrats and, just plain ‘troublemakers’,’ Trump wrote in another post Sunday morning. ‘They have hit 90%, 92%, 93%, and 95%, in various polls, and are all Republican Party records. The General Election numbers are my highest, EVER! People like Strong Borders, and all of the many other things I have done. GOD BLESS AMERICA. MAGA!’ 

This post appeared first on FOX NEWS